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Introduction
Within the European Union 
counterfeiting of medicines has been 
identified as a significant concern for patient 
safety, for industry and for policy makers 
both at EU level and at national level.2 While 
counterfeit medicines have been around for 
some time, the original approach to dealing 
with this problem was to do so in a subtle 
manner so as not to undermine the patient’s 
confidence in medicines and not to cause any 
unnecessary harm to legitimate business.3 
The approach has now changed and all stake 
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holders are urged to become involved and 
give their contribution to managing and 
containing this global problem. Consumers 
and public interest groups are encouraged to 
participate in medicine regulation.4   
Defining the problem
Counterfeit medicines have been defined 
as ‘medicines which are deliberately and 
fraudulently mislabelled with respect to their 
identity and/or source. Counterfeiting can 
apply both to branded and generic products 
and counterfeit products may include products 
with the correct ingredients or the wrong 
ingredients, without active ingredients or with 
insufficient active ingredient or with fake 
packaging.’5
Counterfeit medicines are not just 
substandard medicines, where in the 
latter case there are problems with 
the manufacturing process by a known 
manufacturer. Counterfeit medicines are 
made by (unknown) people with the 
intention to deceive and who have no 
regard whatsoever for patient health and 
safety. Engaging in the counterfeiting of 
medicines has the potential for making 
enormous profits and counterfeiters have the 
possibility of quickly adapting and adjusting 
to different situations and products to 
maximise their profits.6
Over recent years there has been a sharp 
increase in counterfeit medicines seized 
by customs at EU borders. It is estimated 
that in industrialised countries counterfeit 
medicines have a market share of 1%.7 As 
evidenced by reports from various national 
drug agencies, initially counterfeiters 
targeted lifestyle medicines such as 
erectile dysfunction and anti-obesity drugs, 
however they have now shifted their focus 
to lifesaving drugs such as those used in 
the treatment of cardiovascular disease, 
infections and cancers to mention a few.8, 9 
Apart from using the internet, 
counterfeiters are also now targeting 
the licensed distribution chain including 
wholesalers and pharmacies as this gives 
them the ability to deal in large volumes of 
distribution of medicine.
The legitimate distribution chain is a 
rather complex one and offers counterfeiters 
a good opportunity to infiltrate the system. 
Once a counterfeit product has entered 
the legitimate system, it becomes rather 
difficult to detect. When considering the 
EU, counterfeit medicines are usually 
produced outside the EU and then ‘imported 
for export’, i.e. when these products are 
allegedly not placed on the market in the 
EU but enter customs territory under transit 
rules and undergo further minor processing. 
While they should not be made available 
within the EU, these medicines can be 
redirected and enter the legal distribution 
chain. As in the case with Malta, where to 
date no cases of counterfeits were found 
and reported in the legal supply chain, 
counterfeit drugs are often detected in T1 
transit, such as in customs territory where 
non-EU goods are stored and handled.1
The issue of counterfeit medicines was mainly associated with 
developing countries, however it has now become of significant 
concern world-wide. While the exact extent of the problem is still 
unknown, the prevalence of counterfeit medicines is increasing, with 
a shift in focus from life style medicines to life saving medicines. 
As compared to 2005 the EU registered an increase of 380% of 
counterfeit medicines seized at EU borders in 2007.1
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Educational aims
•	 To	increase	awareness	regarding	counterfeit	medicines
•	 To	highlight	the	threat	to	patient	safety
•	 To	dispel	common	misconceptions
•	 To	encourage	health	care	professionals	to	participate	in	medicines	regulation
Issue 16  Summer 2010 Journal of the Malta College of Pharmacy Practice          5
Misconceptions a regarding 
counterfeit medicines
One of the main misconceptions is that 
counterfeiting of medicines is a problem 
which only affects developing countries. 
While the areas which are the most affected 
are indeed developing countries, Europe 
and the rest of the industrialised world is 
increasingly being targeted as can be seen in 
Table 2. In developing countries antibiotics 
and anti-protozoals such as anti-malarial 
medicines are commonly counterfeited 
while in developed countries hormones and 
steroids account for the majority of the cases 
reported.7
It is commonly thought that these 
are harmless copies or concern issues not 
affecting the health of the patient but just 
intellectual property since it is erroneously 
assumed that only branded products are 
targeted. As can be seen from the definition, 
this is not the case as both generics 
and branded products may be targeted 
for counterfeiting. Counterfeiters target 
medicines that can provide them with the 
largest profit and lucrative markets i.e. high 
consumption and expensive medicines are 
main targets.
Another misconception is that it is easy 
to tell the difference between a counterfeit 
medicine and an authentic medicine. This 
is not the case at all. With the technology 
currently available counterfeiters are able 
to make their product nearly identical 
to the original both in the case of the 
appearance of the medicine itself as well as 
the packaging. It often requires laboratory 
analysis to determine if a product is 
counterfeit.
Threat to patient safety
The threat to patient safety is 
significant. Counterfeit medicines could 
possibly not contain the correct active 
ingredient or contain the correct active 
ingredient in sub-therapeutic quantities 
alternatively they may contain toxic 
materials which result in the patient being 
poisoned. 
In 2009 during the Influenza A (H1N1) 
pandemic significantly more reports were 
registered regarding the increased occurrence 
of counterfeit medicines. Counterfeiters 
identified this as a window of opportunity to 
sell fraudulent, adulterated or unauthorized 
antiviral medication or vaccines, via the 
Internet. 11 
 Currently the over-the-counter anti-
obesity drug,  Alli®, has been targeted by 
counterfeiters and is available over the 
internet. The FDA has warned that instead 
of the registered active ingredient orlistat, 
the preparation contains sibutramine, with 
patients taking up to twice the recommended 
maximum dose of the latter drug if they 
are following dosing instructions for Alli®. 
When taken in excess, sibutramine can 
lead to elevated blood pressure, stroke and 
cardiac arrest in persons with a history 
of cardiovascular disease and healthy 
individuals can experience anxiety, nausea, 
palpitations, insomnia and slight increase in 
blood pressure.10
The case of counterfeit anti-diabetic 
traditional medicine reported in China 
found the preparations to contain six times 
the normal dose of glibenclamide which 
leads to the death of two individuals and 
hospitalization of nine people.7 
A number of cases have been 
documented within EU member states. 
A document published in 2008 provides 
examples of cases reported during 
2006/2007.  A seizure of counterfeit heparin 
(Belgium/Germany) was found to contain a 
heparin like contaminant which was added 
to heparin resulting in allergic reactions and 
possibly caused deaths in 81 cases and side-
effects in hundreds of patients.1
This document also lists Malta as having 
‘various’ counterfeit cases of hundreds of 
packs relating to several diseases.1  
As clearly demonstrated, the use 
of counterfeit medicines may result in 
therapeutic failure leading to increased 
morbidity and possibly mortality, which not 
only translates into a negative effect on the 
patient’s health and quality of life but also 
leads to additional medical interventions, 
prolonged hospital stays, additional costs 
for treatment translating into an increased 
burden on the national health care service, 
on the patient and carers.
Unless an effective means of addressing 
this problem is found, once counterfeit 
medicines enter the legal supply chain, 
estimates indicate that they will be a 
significant burden to the EU as indicated by 
the following estimates: 1
Main costs - direct costs
•	 Costs	of	hospitalisations	as	a	
consequence of treatment using 
counterfeit medicines:
 Projected base line until 2020 of 
avoidable hospital admissions is 
Table 1. What encourages counterfeiting of medicines?4
•	 Medicines	attractive	for	counterfeiting
•	 Lack	of	political	will	and	commitment	to	establish	a	strong	national	medicines	authority
•	 Lack	of	appropriate	medicine	legislation
•	 Absence	of,	or	weak	national	medicines	regulatory	agency
•	 Weak	enforcement	including	corruption	and	conflict	of	interest
•	 Shortage	or	erratic	supply	of	medicines
•	 Inappropriate	use	of	medicines
•	 Price	differentials
•	 Inefficient	co-operation	between	stake	holders
•	 Lack	of	control	over	export	medicines
•	 Trade	through	several	intermediaries
•	 Trade	through	free-trade	zones/free	ports
Table 2. Reported cases of 
counterfeit medicines7,8,10
UK
Cialis 20mg
Reductil 15mg
Lipitor 20mg
Zyprexia 10mg
Plavix 75mg
Casodex 50mg
Seretide 250 
Evohaler 8ml pressurised inhalers
Sensodyne original 
Sensodyne Mint 50ml tubes
USA
Xenical 
Alli
United Republic of Tanzania
Metakelfin (anti-malarial)
China 
Anti-diabetic traditional medicine
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estimated to cost the EU between 1.8bn 
EUR-22bn EUR
•	 Costs	occurring	in	an	ambulatory	
setting for treating the consequences 
of a treatment involving counterfeit 
medicines: 
 Projected base line until 2020 of 
avoidable medical treatment at 
community level by primary health care 
doctors is estimated to cost the EU 
between 93m EUR and 1.1bn EUR
Main costs - indirect costs
Using Quality Adjusted Life Years 
(QUALYs), which combine effects on life 
expectancy and quality of life within a 
single measure, with 1 QUALY being equal 
to one year of life expectancy in full health, 
the projected base line cost until 2020 is 
expected to lay between 7.65bn EUR and 
93bn EUR.
Combating counterfeit medicines
All stake holders are encouraged to 
actively participate in combating counterfeit 
medicines. Patients, who are usually the 
first to notice something wrong with their 
medicine e.g. different taste, unusual 
colour, novel side-effects when compared 
to their regular medicines, are encouraged 
to make a report. Pharmacists are expected 
to be aware and vigilant, purchasing their 
medicines only from a reputable source. The 
publication entitled ‘Counterfeit medicines: 
Advice for health care professionals’ provides 
an excellent guide for pharmacists.12 
Medical doctors are strongly advised not to 
encourage patients to obtain their medicines 
outside the legitimate supply chain, which in 
Malta, are only licensed pharmacies.
At a global level The World Health 
Organisation set up the International Medical 
Products Anti-Counterfeiting Taskforce 
(IMPACT) which is comprised of international 
organizations, non-governmental 
organizations, enforcement agencies, 
pharmaceutical manufacturers associations 
and drug and regulatory authorities. Its aim 
is to halt the production, trading and selling 
of fake medicines around the globe.13
At a national level Malta is actively 
participating in the Council of Europe 
Working group on the Pharma package where 
one of its’ pillars is the topic of counterfeit 
medicines. This group’s aim in the Pharma-
package pillar is to submit a proposal for a 
Directive of the European Parliament and of 
the Council amending Directive 2001/83/EC 
with regards to the prevention of entry into 
the legal supply chain of medicinal products 
which are falsified in relation to their 
identity, history or source. Once approved by 
the EU parliament this directive amending 
directive 2001/83 will be transposed into 
national legislation leading to all EU member 
states having harmonised legislation with 
regards to counterfeit medicines.14
 Conclusion
It is essential that healthcare 
Key points
•	 Counterfeit	medicines	are	medicines	that	are	deliberately	and	fraudulently	mislabelled	
with respect to identity and/or source
•		 Use	of	counterfeit	medicines	can	result	in	treatment	failure	or	even	death	
•	 Erosion	of	public	confidence	in	health-delivery	systems	may	result	following	use	and/or	
detection of counterfeit medicines
•	 Both	branded	and	generic	products	are	subject	to	counterfeiting
•	 Patients	should	never	be	encouraged	to	obtain	medicines	outside	the	legitimate	supply	
chain
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